United Biopharma (Ubp), A Taiwan-Based Late Clinical-Stage Biopharmaceutical Company, Has Announced The Approval Of A Phase 2 Clinical Trial With Novel Anti-Ige Monoclonal Antibody Ub-221 By The Taiwan Food And Drug Administration (Tfda).This Phase 2 Clinical Trial (Double-Blind, Placebo-Controlled) Aims To Evaluate The Efficacy Of Ub-221 As A Long-Acting Add-On Therapy For Treatment Of Chronic Spontaneous Urticaria (Csu) And Provide Evidence Of The Therapeutic Potential Of Two High-Dose Ub-221 Treatments Over A 6-Month Period.Spontaneous Urticaria Is Categorized Into Acute ( Six Weeks) Variants. With An Incidence Rate Of 0.5
